109RO Continuous relationship between KELIM chemosensitivity and survival benefit from chemotherapy intensification (standard or dose-dense; with/without bevacizumab): ICON8 & 8B

B You, O Colomban, D Radice, A Gentry-Maharaj, P Corbaux, G Freyer, I McNeish, JA Ledermann, AR Clamp